Dyadic International (DYAI) Accounts Payables (2017 - 2026)
Dyadic International (DYAI) posted Accounts Payables of $1.1 million for Q1 2026, up 24.42% sequentially from $852024.0 in Q4 2025, and up 136.42% YoY from $448390.0 in Q1 2025.
Dyadic International (DYAI) Accounts Payables (2017 - 2026) Analysis & Trends
Dyadic International has reported Accounts Payables for 10 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Accounts Payables rose 136.42% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 136.42% YoY) and the FY2025 annual result came in at $852024.0, up 76.65% from the prior year.
- Accounts Payables rose to $1.1 million in Q1 2026 per DYAI's latest filing, from $852024.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $34.2 million in Q1 2022 and troughed at $34406.0 in Q3 2022.
- A 5-year average of $2.6 million and a median of $656445.0 in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables jumped 79482.2% in 2022, then tumbled 97.75% in 2023.
- Over 5 years, Accounts Payables stood at $1.3 million in 2022, then slumped by 48.57% to $656445.0 in 2023, then fell by 26.53% to $482320.0 in 2024, then jumped by 76.65% to $852024.0 in 2025, then climbed by 24.42% to $1.1 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.1 million, $852024.0, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | 1.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 852,024.00 |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 84,223.00 |
| Mar 31, 2025 | 448,390.00 |
| Dec 31, 2024 | 482,320.00 |
| Sep 30, 2024 | 54,215.00 |
| Jun 30, 2024 | 432,521.00 |
| Mar 31, 2024 | 661,243.00 |
| Dec 31, 2023 | 656,445.00 |
| Sep 30, 2023 | 600,148.00 |
| Jun 30, 2023 | 905,876.00 |
| Mar 31, 2023 | 770,371.00 |
| Dec 31, 2022 | 1.28 Mn |
| Sep 30, 2022 | 34,406.00 |
| Jun 30, 2022 | 102,851.00 |
| Mar 31, 2022 | 34.21 Mn |
| Dec 31, 2021 | 1.55 Mn |
| Sep 30, 2021 | 957,802.00 |
| Jun 30, 2021 | 2.43 Mn |